Latest News RSS

Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease

 PR NewsWire March 3, 2017 Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease Concord, MA-- March 3, 2017-- Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary antibody delivery technology with recombinant human acid alpha-glucosidase (rhGAA) to improve the delivery of...

Read more →

SAVE THE DATE

Read more →

December 8, 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease

December 8, 2016Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study ofNovel Treatment Paradigm for Pompe DiseaseATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile as Predicted Based on Previously Reported Preclinical Data Biomarkers of Muscle Damage are Generally Stable or Trending Towards Improvement...

Read more →

Upcoming Meetings/Events

DUKE POMPE PATIENT MEETING 

 

 

 

 

 

Medical Alert Brochure